Publications by authors named "Davide Lovera"

Claim this Profile
C
Cost-effectiveness of implant movement analysis in aseptic loosening after hip replacement: a health-economic model.
Davide Lovera, Olof Sandberg, Maziar Mohaddes, Hanna Gyllensten

Cost Eff Resour Alloc· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Michele Cea, Antonia Cagnetta, Chirag Acharya, Prakrati Acharya, Yu-Tzu Tai, Davide Lovera

Clin Cancer Res· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma.
Antonia Cagnetta, Davide Lovera, Raffaella Grasso, Nicoletta Colombo, Letizia Canepa

Biomed Res Int· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liposomal daunorubicin, fludarabine, and cytarabine (FLAD) as bridge therapy to stem cell transplant in relapsed and refractory acute leukemia.
Enrico De Astis, Marino Clavio, Anna Maria Raiola, Anna Ghiso, Fabio Guolo, Davide Lovera

Ann Hematol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".
Marino Clavio, Fabio Cruciani, Paola Minetto, Fabio Guolo, Filippo Ballerini, Davide Lovera

Ann Hematol· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis